| Center Member |
Department |
Research Description |
| Peggi M. Angel, Ph.D. |
Cell and Molecular Pharmacology and Experimental Therapeutics |
MS-analysis of extracellular matrix in liver disease |
| Tim Barnoud, Ph.D. |
Biochemistry and Molecular Biology
|
Heat shock proteins and p53 variants in cancer risk |
| Katherine E. Chetta, M.D. |
Pediatrics |
HAMLET and oleic acid in preterm intestinal disease |
| Toros Dincman, M.D., Ph.D. |
Hematology/Oncology |
Genomic, transcriptional and post-transcriptional mechanisms in tumorigenesis |
| Richard R. Drake, Ph.D. |
Cell & Molecular Pharmacology |
MS approaches for glycan and glycoprotein markers of GI disease |
| Stephen A. Duncan, DPhil |
Regenerative Medicine & Cell Biology |
iPSC hepatocyte modeling of metabolic liver disease |
| Valerie Durkalski-Mauldin, M.P.H., Ph.D. |
Public Health Sciences |
Clinical trial methodology and implementation, digestive diseases |
| Badih J. Elmunzer, M.D., MSc |
Medicine |
GI endoscopy, ERCP, colorectal cancer screening |
| Amy C. Engevik, Ph.D. |
Regenerative Medicine & Cell Biology |
Microvillus Disease (MVID) and cholestasis |
| Mindy A. Engevik, Ph.D. |
Regenerative Medicine & Cell Biology |
Microbial-host crosstalk in the intestinal mucus layer |
| Lewis J. Frey, Ph.D. |
Public Health Sciences |
Artificial Intelligence approaches for modeling liver disease |
| Wenjian Gan, Ph.D. |
Biochemistry and Molecular Biology |
Kinase pathways in liver disease and cancer |
| Silvia Guglietta, Ph.D. |
Microbiology and Immunology |
Complement factor impact on immune response and gut microbiota in IBD |
| Denis C. Guttridge, Ph.D. |
Pediatrics |
Pancreatic cancer and cachexia |
| Jessica H. Hartman, Ph.D. |
Biochemistry and Molecular Biology |
Metabolism and xenobiotic and mechanistic toxicology in liver disease |
| Jessica Hathaway-Schrader, Ph.D. |
Pathology & Laboratory Medicine |
Role of complement signaling and commensal flora in skeletal development |
| Aaron Hobbs, Ph.D. |
Pharmacology |
Ras mutations in pancreatic cancer
|
| Antonis Kourtidis, Ph.D. |
Regenerative Medicine & Cell Biology |
RNAi regulation at colonic epithelial cell junctions |
| John J. Lemasters, M.D., Ph.D. |
Drug Discovery & Biomedical Sciences |
Mitochondria in ethanol and drug-induced liver injury |
| Anand S. Mehta, Ph.D. |
Cell & Molecular Pharmacology |
Glycoproteomics in liver cancer |
| Eric G. Meissner, M.D., Ph.D. |
Medicine |
Hepatitis C viral infection |
| Jorge Múnera, Ph.D. |
Regenerative Medicine and Cell Biology |
iPSC colonic organoids for modeling GI disease |
| Anna-Liisa Nieminen, Ph.D. |
Drug Discovery & Biomedical Sciences |
Iron homeostasis and liver injury |
| Paul J. Nietert, Ph.D. |
Public Health Sciences |
Hierarchical data analysis, truncated distributions, randomization in clinical trials |
| John P. O'Bryan, Ph.D. |
Cellular and Molecular Pharmacology |
Therapeutics targeting RAS function in GI cancer |
| Don C. Rockey, M.D. |
Medicine |
Liver fibrosis and portal hypertension |
| Natalie Saini, Ph.D. |
Biochemistry and Molecular Biology |
Environmental exposures in HCC |
| Andrew D. Schreiner, MD, MSCR |
Medicine |
EHR-based primary care management of chronic liver disease |
| Garth R. Swanson, M.D. |
Medicine |
Circadian rhythm and IBD |
| Chenthamarakshan Vasu, Ph.D. |
Microbiology & Immunology |
Mucosal-microbiota-dietary interactions in colitis |
| Dirk J. van der Windt, M.D., Ph.D. |
Surgery |
Mechanisms of inflammation and injury in liver transplantation |
| Kristin Wallace, Ph.D. |
Public Health Sciences |
Disparities in colorectal cancer |
| Hongjun Wang, Ph.D. |
Surgery |
Novel therapeutics for chronic pancreatitis |
Caroline Westwater, Ph.D.
|
Microbiology & Immunology |
Candida infections in GI disease
|
| Yuan Zhai, M.D., Ph.D. |
Surgery |
Ischemia/reperfusion injury in liver transplantaton |
| Zhi Zhong, M.D., Ph.D. |
Drug Discovery & Biomedical Sciences |
Targeting mitochondrial dysfunction in liver disease |
